INNOTEST® β-AMYLOID(1-42)

The INNOTEST β-AMYLOID(1-42) is a solid-phase enzyme immunoassay for the quantitative determination of β-amyloid(1-42) in human cerebrospinal fluid (CSF).

The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression.1-6

    Contact sales for information
    CE marked (IVDR)
    INNOTEST® β-AMYLOID(1-42)

    Product number 81576

    96 Tests
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Contact sales for information
    • Details
    • Conditions of sale
    • Citations
    • Documentation
    • Insights
    • Product inquiry
    • Related products

    • Details

      Features & Benefits                   

      • User-friendly enzyme  immunoassay, standard technology
      • Generic and color-coded components
      • Easily automated on microplate processor (generic components)
      • Ready-to-use Calibrators reduce inter and intra run variation
      • Run Validation Controls for assay run validation
      • Sample volume: 25 µL CSF. Duplicate testing is strongly recommended and requires 2 x 25 µL CSF.
      • Limit of Detection: 65 pg/mL
        Calibrator range: 62,5 to 4000 pg/mL
      • This assay should be used in combination with the Aβ(1-42) CAL-RVC pack, article no. 81577.

        
      References

      1. Andreasen et al. Evaluation of CSF-tau and CSF- Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.
      2. Sunderland et al. Decreased b-amyloid1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer disease. Journal of the American Medical Association 2003;289:2094-2103.
      3. Hansson et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234
      4. Mattsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302(4): 385-393.
      5. Tabaraud et al. Alzheimer CSF biomarkers in routine clinical setting. Acta Neurol Scand. 2012; 125(6): 416-23.
      6. Buchhave et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69(1): 98-106.

      Additional useful information about Alzheimer’s disease can be found on the following websites: The Alzheimer forum site:

       
      Disclaimer

      A license regarding amyloid beta antibodies contained in this product under patents US 5750349 has been obtained from Takeda Pharmaceutical Company Limited. Furthermore, a license for the use of amyloid beta monoclonal antibodies contained in this product under patents US 6114133, US7811769, and EP 0792458 has been obtained from Eli Lilly and Company.

    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • Citations

    • Insights

    • Product inquiry

      CAPTCHA

      The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

      For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

      If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

    Veuillez confirmer que vous êtes un professionnel de la santé

    Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

    Choose your country or region

    Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
    The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.